Literature DB >> 15699753

T and B cell cooperation: a dance of life and death.

Alain Bernard1, Sylvie Coitot, Aurore Brémont, Ghislaine Bernard.   

Abstract

In order for the body to develop a good antibody response, B cells need to react intimately with antigen specific T cells. Experimental evidence using hapten-carriers revealed that T and B cells do not recognize the same epitope and this led to the view that the physical contact is mediated by the antigen. Although the modern concept of antigen presentation has changed our perception on how the antigen can bridge both cells, the basic virtues of earlier bridging models remain. Over the past few years, a number of surface ligand-receptor pathways have been described, most of them belonging either to the CD28/B7 Ig or to the TNF/TNFR-like families. These act in concert, whether they are agonist or antagonist, in a timely and spatially organized manner. They form cascades of successive induction and recruitment to ensure that T-B cooperation is closely controlled at all stages of antibody induction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699753     DOI: 10.1097/01.tp.0000153290.75695.31

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Syk-dependent actin dynamics regulate endocytic trafficking and processing of antigens internalized through the B-cell receptor.

Authors:  Delphine Le Roux; Danielle Lankar; Maria-Isabel Yuseff; Fulvia Vascotto; Takeaki Yokozeki; Gabrielle Faure-André; Evelyne Mougneau; Nicolas Glaichenhaus; Bénédicte Manoury; Christian Bonnerot; Ana-Maria Lennon-Duménil
Journal:  Mol Biol Cell       Date:  2007-06-27       Impact factor: 4.138

2.  B cells help alloreactive T cells differentiate into memory T cells.

Authors:  Y-H Ng; M H Oberbarnscheidt; H C K Chandramoorthy; R Hoffman; G Chalasani
Journal:  Am J Transplant       Date:  2010-09       Impact factor: 8.086

3.  The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.

Authors:  Richard B Kennedy; Gregory A Poland
Journal:  Virology       Date:  2010-10-18       Impact factor: 3.616

4.  Innate and adaptive immune responses are tolerized in chimeras prepared with nonmyeloablative conditioning.

Authors:  Hong Xu; Ziqiang Zhu; Yiming Huang; Larry D Bozulic; Lala-Rukh Hussain; Jun Yan; Suzanne T Ildstad
Journal:  Transplantation       Date:  2012-03-15       Impact factor: 4.939

5.  Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers.

Authors:  S Cho; S Dong; K N Parent; M Chen
Journal:  J Drug Target       Date:  2015-08-25       Impact factor: 5.121

Review 6.  Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.

Authors:  Satoshi Nagata; Ira Pastan
Journal:  Adv Drug Deliv Rev       Date:  2009-08-11       Impact factor: 15.470

7.  Peripheral blood CD27+ IgG+ B cells rapidly proliferate and differentiate into immunoglobulin-secreting cells after exposure to low CD154 interaction.

Authors:  Jessie F Fecteau; Annie Roy; Sonia Néron
Journal:  Immunology       Date:  2008-11-07       Impact factor: 7.397

Review 8.  Allergy-associated T cell epitope repertoires are surprisingly diverse and include non-IgE reactive antigens.

Authors:  April Frazier; Veronique Schulten; Denise Hinz; Carla Oseroff; John Sidney; Bjoern Peters; Alessandro Sette
Journal:  World Allergy Organ J       Date:  2014-10-22       Impact factor: 4.084

Review 9.  The need for inducing tolerance in vascularized composite allotransplantation.

Authors:  Kadiyala V Ravindra; Hong Xu; Larry D Bozulic; David D Song; Suzanne T Ildstad
Journal:  Clin Dev Immunol       Date:  2012-10-31

10.  Prevalence of ZAP-70, LAT, SLP-76, and DNA methyltransferase 1 expression in CD4+ T cells of patients with systemic lupus erythematosus.

Authors:  Radosław Januchowski; Mariusz Wudarski; Hanna Chwalińska-Sadowska; Paweł P Jagodzinski
Journal:  Clin Rheumatol       Date:  2007-05-11       Impact factor: 3.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.